Evropska unija - estonščina - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Evropska unija - estonščina - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - rinnanäärmed - endokriinse ravi, anti-östrogeene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - või perimenopausal naiste kombineeritud ravi palbociclib tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.

Evropska unija - estonščina - EMA (European Medicines Agency)

takeda pharma a/s - fentanüül citrate - pain; cancer - valuvaigistid - instanyl on näidustatud läbimurdevalu raviks täiskasvanutel, kes juba saavad säilitusravi opioididega kroonilise vähivalu. läbimurrevalu on vahelduv valu ägenemine, mis esineb muidu kontrollitud püsiva valu taustal.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 25mg 110tk; 25mg 28tk; 25mg 56tk; 25mg 30tk; 25mg 100tk; 25mg 90tk; 25mg 70tk; 25mg 98tk; 25mg 84tk

Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 50mg 30tk

Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 12,5mg 30tk

Estonija - estonščina - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 37,5mg 84tk; 37,5mg 30tk; 37,5mg 56tk; 37,5mg 28tk

Estonija - estonščina - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Estonija - estonščina - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 12,5mg 30tk

Estonija - estonščina - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 25mg 28tk